Navigation Links
Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011
Date:4/13/2011

bility to obtain, use or successfully integrate third-party licensed technology; and breach of our security by third parties.  See our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and other public filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business.  The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.


'/>"/>
SOURCE Allscripts Healthcare Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. mPay Gateway Teams With Allscripts to Provide Point-of-Care Patient Payment Tools to Physician Practices Nationwide
2. Northeast Alabama Regional Medical Center Selects Allscripts to Automate Emergency Department and Connect Caregivers
3. Maimonides Medical Center Implements Allscripts Care Management Solution
4. Allscripts to Announce Fiscal Fourth Quarter and Year-End Results
5. Central Penn Management Group Selects Allscripts Electronic Health Record for Physicians Alliance
6. Sharp HealthCare Selects Allscripts Community Record to Deliver End-to-End Health Information Connectivity for San Diego Physicians and Hospitals
7. MedWest Health System Selects Allscripts Electronic Health Record and Practice Management for Employed Physicians
8. Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community
9. Allscripts to Announce Third Quarter 2010 Results on November 8, 2010
10. Allscripts MyWay™ Electronic Health Record Receives ONC-ATCB Certification by Drummond Group
11. Allscripts Sunrise Electronic Health Record Receives ONC-ATCB 2011/2012 Certification as Complete EHR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences International, ... primary efficacy endpoint in the Phase 3 clinical ... for the treatment of painful diabetic neuropathy did ... showed statistically significant improvement over placebo.  In addition, ... observed.  The results of this trial provide data ...
(Date:3/29/2015)... 2015  Three-month paliperidone palmitate, an investigational atypical ... placebo in patients with schizophrenia, according to a ... in the Journal of the American ... Results of the study served as the basis ... for three-month paliperidone palmitate injection to treat schizophrenia ...
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
... Sunridge International (OTC Bulletin Board: ... its first order to Ameco Medical Equipment L.L.C., ...  AME plans to start its marketing rollout of ... conducting a short study to gain reimbursement approval ...
... Strong Performance in Key Safety and Efficacy Measures at Two Years in ... Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®,-- Data Show ... Key Safety and Efficacy... -- ABBOTT PARK, Ill., Sept. 23 ... ...
Cached Medicine Technology:Sunridge Ships First Order to the Middle East 2Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 2Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 3Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 5Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 6Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 7Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 8Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 9
(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... Linda, CA (PRWEB) March 30, 2015 ... challenging due to the use of cellular models that ... not the entirety of the disease. , A ... human cells to precise specifications has created ... to develop environmentally and genetically driven in vitro models ...
(Date:3/29/2015)... Calif. (PRWEB) March 30, 2015 Over ... menopause-related symptoms tied to undiagnosed autoimmune, thyroid, or hormone ... thyroid disorders, has personally treated hundreds of patients dealing ... are unaware of the treatment options for their ailments. ... offers solutions to women living with fatigue, brain fog, ...
(Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, ... Accreditation on 11th January 2015. The accreditation from ... Providers) comes as a true recognition of the ... RxDx., With Telerad RxDx being the first healthcare ... marks a major achievement and a significant step ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:How to Turn Mid-life into the Good Life 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
... their overactive bladder (OAB) medication said it was because it ... to research in the May issue of the urology journal ... men with enlarged prostates and people with bladder infections are ... bladder problems. The team surveyed 6,577 adults who said ...
... leading cause of severe diarrhea and dehydration among ... dramatic decline in U.S. hospitalization rates for acute ... available online ( http://www.journals.uchicago.edu/doi/abs/10.1086/652403 ), published in the ... Infectious Diseases . Worldwide, rotavirus infection ...
... ... Issues Arise , ... (PRWEB) May 13, 2010 -- From everyday encounters to special gatherings and events, those ... having a baby. Knowing how to respond and how much you are comfortable sharing ...
... ... Capital Confirmation, Inc. its 2010 Best in Business winner for the 1 – 25 employee ... (PRWEB) ... of secure audit confirmation services, was named “Best in Business” in the 1 – 25 ...
... ... best pharmaceutical value-added programs and account managers among key managed care influencers. ... Health ... market research project that provides strategic and tactical information to assist pharmaceutical manufacturers ...
... women most at risk, researchers say , THURSDAY, May 13 ... common genes trigger cellular changes that can lead to breast ... expression of the genes -- estrogen receptor alpha and p53 ... the rodents likely mimic natural variations of the two genes ...
Cached Medicine News:Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 2Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 3Health News:Study finds rotavirus vaccine greatly reduces hospitalizations for acute gastroenteritis in children 2Health News:Attain Fertility Offers 3 Steps to Protect Emotional Well-being While Trying to Get Pregnant 2Health News:Attain Fertility Offers 3 Steps to Protect Emotional Well-being While Trying to Get Pregnant 3Health News:Capital Confirmation Named Best In Business by Nashville Business Journal 2Health News:Capital Confirmation Named Best In Business by Nashville Business Journal 3Health News:HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings 2Health News:HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings 3Health News:Small Changes in Two Genes May Trigger Breast Cancer 2
... the only isosmolar contrast medium (IOCM™) available in ... of blood, VISIPAQUE was designed for patient safety ... medium formulated with sodium and calcium in a ... FDA approval for use in children over one ...
The cordless Simon Dermatome with rechargeable battery is used to harvest split-thickness skin grafts and for debridement....
Hand surgery basic instrument set with round handled instruments...
Dilator...
Medicine Products: